title: Moving to tolerance: clinical application of T regulatory cells.
abstract: Decreasing the incidence of chronic rejection and reducing the need for life-long immunosuppression remain important goals in clinical transplantation. In this article, we will review how regulatory T cells (Treg) came to be recognized as an attractive way to prevent or treat allograft rejection, the ways in which Treg can be manipulated or expanded in vivo, and the potential of in vitro expanded/generated Treg for cellular therapy. We will describe the first regulatory T cell therapies that have been or are in the process of being conducted in the clinic as well as the safety concerns of such therapies and how outcomes may be measured.
authors.affiliation: Department of Surgery, University of British Columbia, Canada.
authors.forename: Alicia N
authors.initials: AN
authors.lastname: McMurchy
authors.forename: Andrew
authors.initials: A
authors.lastname: Bushell
authors.forename: Megan K
authors.initials: MK
authors.lastname: Levings
authors.forename: Kathryn J
authors.initials: KJ
authors.lastname: Wood
mesh_terms: D000818:Animals; D064987:Cell- and Tissue-Based Therapy / Q000009:adverse effects / Q000639:trends; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005060:Europe; D006084:Graft Rejection / Q000175:diagnosis / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D056747:Immunomodulation; D016377:Organ Transplantation; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000637:transplantation; D023001:Transplantation Tolerance; D016896:Treatment Outcome